Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology, Inc. officer Teresa Bair reported a proposed sale of 8,442 shares of common stock, with an aggregate market value of $90,835.92 and an approximate sale date of September 28, 2026. The notice also lists 31,487 restricted stock units sold on August 19, 2026, valued at $397,829.73, under a 10b5-1 sales heading.
Kura Oncology, Inc. (KURA) officer Kathleen Ford reported a proposed sale of 6,906 shares of common stock with an aggregate market value of $74,308.56, with September 28, 2026 listed as the approximate sale date. The notice names Morgan Stanley Smith Barney LLC as broker and lists September 27, 2026 as the acquisition date, with “PSU” as the nature of acquisition.
A Rule 144 notice names Kura Oncology, Inc. (KURA) as the issuer and identifies Officer Thomas James Doyle for a proposed sale of 4,607 shares of common stock, with an aggregate market value of $49,571.32 and an approximate sale date of September 28, 2026. The shares are listed as acquired from the issuer as PSUs on September 27, 2026; Morgan Stanley Smith Barney LLC is named in the broker field. Teresa Bair signed as attorney-in-fact for Thomas Doyle.
Kura Oncology, Inc. officer Brian Powl reported a proposed sale of 8,000 common shares, with an aggregate market value of $86,080.00. Morgan Stanley Smith Barney LLC is named as the broker. Separately, Brian Powl's prior three-month sales included 4,345 common shares sold on August 21, 2026, for $51,663.26; these are identified as 10b5-1 sales.
Kura Oncology, Inc. Chief Scientific Officer Burrows Francis exercised 30,000 fully vested stock options on September 24, 2026, at an exercise price of $6.15 per share, acquiring 30,000 common shares. He sold 20,726 shares that day at a weighted average price of $10.8325 per share. The transaction was described as a cashless exercise and sale of a portion to cover estimated payroll tax liability; the sale trades ranged from $10.82 to $10.85. The option row reported 0 options following the transaction and an expiration date of January 22, 2027.
Kura Oncology, Inc. (KURA) lists a proposed sale by officer Francis John Burrows of 20,726 common shares, with an aggregate market value of $224,514.40 and an approximate sale date of September 24, 2026. The notice says the shares were acquired from the issuer through stock option exercise on September 24, 2026, and identifies Morgan Stanley Smith Barney LLC as broker.
Kura Oncology, Inc. (KURA) reported that Chief Financial Officer Jennifer Fulk received a grant of stock options covering 450,000 shares of common stock on September 8, 2026. The options have an exercise price of $12.52 per share and expire on September 7, 2036, and no shares were bought or sold.
The grant was reported as made pursuant to a Rule 10b5-1 trading plan. According to the vesting terms, one-fourth of the options vest on the one-year anniversary of the vesting commencement date, with the remainder vesting in monthly installments thereafter.
Kura Oncology, Inc. (KURA) reported that its Chief Financial Officer, Jennifer Fulk, has filed an initial statement of beneficial ownership of securities on Form 3. The submission lists no reportable transactions, acquisitions, or dispositions of Kura Oncology securities and shows no derivative positions.
Kura Oncology, Inc. (symbol: KURA) is the issuer of record for a Form 8-K filing submitted to the SEC.
Kura Oncology, Inc. (KURA) appointed Jennifer Fulk as Chief Financial Officer, principal financial officer and principal accounting officer effective September 8, 2026, replacing Troy E. Wilson, Ph.D., J.D. and Thomas Doyle in those specific roles. Fulk brings prior CFO and operating experience at Soleno Therapeutics, 120Water, Talkspace and Eli Lilly and Company.
Under her September 8, 2026 employment agreement, Fulk receives a $550,000 annual base salary, is eligible for an annual discretionary bonus of up to 45% of base salary, an option to purchase 450,000 shares of common stock and a one-time performance-based restricted stock unit award covering 173,438 shares. The option vests over four years and the PSUs vest in six installments based on revenue, clinical and regulatory milestones.
The agreement provides cash severance, COBRA premium payments, option exercise extensions and, in a qualifying termination in connection with a Corporate Transaction, additional cash, extended COBRA coverage and full acceleration of all outstanding equity awards, with performance-based awards vesting at target.